Compare Invesco Galaxy Bitcoin ETF (BTCO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Galaxy Bitcoin ETF vs Sanofi SA — how do they compare? Invesco Galaxy Bitcoin ETF trades at $65.08, while Sanofi SA trades at $43.53 (market cap $102.91B). The key difference: Sanofi SA pays a 5.6% dividend while Invesco Galaxy Bitcoin ETF pays none. Which is the better fit depends on your goals.
| BTCO | SNY | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $125.14 | $52.34 |
52-Week Low | $58.40 | $41.33 |
Market Cap | — | $102.91B |
Enterprise Value | — | $119.39B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTCO trades at $61.86, down 2.67% today amid mixed technical signals with a bullish overall trend but bearish moving averages. The stock faces resistance near $64-65 while finding support around $62-63. Financial ratios remain unavailable in current data, requiring deeper fundamental analysis.
The stock shows technical resilience despite recent selling pressure, with key support levels holding. Investment appeal depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and competitive pressures in its sector.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
